Slides on Key Decisions in HIV Care: Managing Suboptimal CD4+ Cell Count Increase Despite Suppressive ART

Learn the data supporting guideline recommendations about the consequences of suboptimal CD4+ cell count, whether to intensify therapy, switch ART, and more.
William R. Short, MD, MPH, AAHIVS
Format: Microsoft PowerPoint (.ppt)
File Size: 428 KB
Released: November 3, 2021

Acknowledgements

Educational grant provided by:
Gilead Sciences, Inc.
Janssen Therapeutics, Division of Janssen Products, LP
ViiV Healthcare

Related Content

Discussion of key considerations for switching antiretroviral therapy when the patient is pregnant, from Clinical Care Options (CCO)

person default Annette Haberl, MD William R. Short, MD, MPH, AAHIVS Released: November 23, 2022

Prof Don Smith discusses new HIV data from IDWeek 2022 on long-acting cabotegravir plus rilpivirine in this commentary from Clinical Care Options (CCO)

Don Smith, MD Released: November 22, 2022

Expert discussion of HIV Glasgow 2022 data on optimizing islatravir dosing based on lymphocyte changes and IDWeek 2022 data on LA CAB + RPV real-world effectiveness in the US OPERA Cohort, from Clinical Care Options (CCO)

Brenda E. Crabtree Ramírez, MD Released: November 22, 2022

Clinical Care Options (CCO) downloadable slides from Drs Joseph Eron, Karine Lacombe, Chloe Orkin, and Babafemi Taiwo on HIV data from IDWeek and HIV Glasgow 2022

Joseph J. Eron, Jr., MD Karine Lacombe, MD, PhD Chloe Orkin Photo Chloe Orkin, MBChB, FRCP, MD Babafemi Taiwo, MBBS Released: November 22, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings